The World Health Organization (WHO) reported that more than 2.2 million women were diagnosed with breast cancer in 2020, resulting in 685,000 deaths. Since the 1980s, improvements in diagnosis, thanks to early tumour detection, have reduced mortality from this form of cancer by 40% in high-income countries. But treatment, which usually combines surgery and radiotherapy, is often a traumatic experience for patients, especially when the entire breast is removed. To solve the problem, the Israeli company IceCure has developed the ProSense system for cryoablation of breast tumours.
How it works is that the doctor, guided by ultrasound, percutaneously introduces the probe-equipped device into the tumour. Liquid nitrogen is then injected into the tumour area, reducing the temperature to -160°C and destroying the cancer cells. Compared to surgery, cryoablation is faster, less painful, and less expensive. In April 2021, the ProSense system was granted Breakthrough Device Designation by the Food and Drug Administration (FDA). It is approved and marketed in Europe and the United States to treat certain forms of breast cancer. The device could also be used to treat other tumours. Listed on the Tel Aviv Stock Exchange, IceCure posted sales of $2.75 million in the first nine months of 2021, up 11% from the same period a year earlier. A buy recommendation has been issued on the stock.